+0.06 (+6.47%)
Dilution Risk
R&D Expenses
2.95 M
Operating CF
-4.36 M
Total Assets
5.94 M
Total Liabilities
3.34 M
Equity
2.60 M
D/E Ratio
12,345
Cash Position
1.48 M
Monthly Burn
1.46 M
Runway
0 mo
Burn Trend
StableSEC Filing
Apr 30, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 interim results example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Dermatologic System | ||
Phase 1/2 interim results example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Dermatologic System | ||
Phase 1/2 interim results example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Dermatologic System |
Dated clinical, regulatory & corporate events for FibroBiologics, Inc.
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tolerogenic Fibroblasts Monoclonal antibody | Multiple Sclerosis, Relapsing-Remitting | Phase 1 | NCT05080270 | 18% | $345M | COMPLETED | 5 | - | - | Jun 8, 2021 | - | Oct 22, 2021 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
fibroblasts | demyelinating diseases, including multiple sclerosis | — | 2025-04-02 | statistically significant increase in myelin expression within seven weeks after both single and multiple dose fibroblast treatments Read More | FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair Read More | |
fibroblasts | demyelinating diseases, including multiple sclerosis | — | 2025-04-02 | statistically significant increase in myelin expression within seven weeks after both single and multiple dose fibroblast treatments Read More | FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair Read More | |
fibroblasts | demyelinating diseases, including multiple sclerosis | — | 2025-04-02 | statistically significant increase in myelin expression within seven weeks after both single and multiple dose fibroblast treatments Read More | FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair Read More |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
FibroBiologics has appointed Dr. Kathleen "Kate" Rubins to its Board of Directors. Dr. Rubins, a retired NASA astronaut and microbiologist, has been part of the company's Scientific Advisory Board since 2022. Her expertise in immune response and cell therapy is expected to guide the company's development of fibroblast-based treatments for chronic diseases.
Read more →FibroBiologics has successfully completed the manufacturing of the third batch of its CYWC628 drug product for a Phase 1/2 clinical trial focused on diabetic foot ulcers. The batch meets cGMP standards and is undergoing safety and quality testing. The company anticipates having enough product to complete the trial, potentially leading to cost savings and surplus doses for future research.
Read more →FibroBiologics, a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. CEO Pete O'Heeron and CSO Hamid Khoja will engage in a fireside chat on June 30, 2026. The company aims to showcase its advancements in fibroblast-based therapeutics and will be available for one-on-one meetings during the event.
Read more →FibroBiologics has successfully closed a private placement raising $3 million, with the potential for an additional $6 million through warrant exercises. The company plans to use the proceeds for working capital and general corporate purposes. The offering was conducted under Nasdaq rules, and the securities are not registered under the Securities Act.
Read more →FibroBiologics, Inc. has announced a private placement of common stock and warrants, aiming to raise up to $9 million. The initial $3 million will be supplemented by potential proceeds of $6 million from warrant exercises. The offering is set to close around June 29, 2026, pending customary conditions. The funds will support working capital and corporate purposes.
Read more →FibroBiologics has announced that the USPTO issued a Notice of Allowance for its patent application on the therapeutic use of fibroblasts in wound healing. The patent includes 19 claims related to the topical administration of 3D spheroid fibroblasts for treating chronic wounds, particularly in patients with diabetes. This aligns with the company's lead program, CYWC628, currently in Phase 1/2 trials for diabetic foot ulcers.
Read more →FibroBiologics has initiated patient dosing in its Phase 1/2 clinical trial for CYWC628, aimed at treating diabetic foot ulcers. The first doses were administered in early June 2026, with ongoing manufacturing efforts to support the trial. The investigational therapy is designed to enhance wound healing by utilizing fibroblast cells. The company emphasizes the importance of its consistent manufacturing capabilities for clinical success.
Read more →FibroBiologics has initiated its Phase 1/2 clinical trial for CYWC628, targeting diabetic foot ulcers. The trial will enroll up to 120 patients and assess the safety and efficacy of this novel fibroblast-spheroid therapy. The first patients have been dosed, marking a significant milestone for the company. Results from the trial could provide crucial insights into chronic wound management.
Read more →FibroBiologics presented promising preclinical data for its CYPS317 program targeting psoriasis at the Society for Investigative Dermatology Annual Meeting. The data highlighted that HDF spheroids effectively reduced disease severity and maintained a better safety profile than single-cell preparations. The findings suggest significant potential for targeted immunomodulation in treating chronic psoriasis.
Read more →FibroBiologics has filed a provisional patent application for an oral administration system for fibroblast-based therapeutics. This innovative platform aims to protect these therapeutics during transit through the gastrointestinal tract, potentially transforming treatment for chronic gastrointestinal disorders. The application includes various delivery architectures designed to ensure efficacy and viability.
Read more →FibroBiologics is advancing its fibroblast-based therapeutic platform to target Hantavirus, a severe respiratory illness. This expansion follows preclinical studies indicating that fibroblasts can mitigate inflammatory responses and promote tissue repair. The company plans to engage with regulatory authorities to establish a clinical evaluation pathway for Hantavirus pulmonary syndrome (HPS) patients.
Read more →FibroBiologics has announced the initiation of a clinical trial for its lead program, CYWC628, aimed at treating diabetic foot ulcers, a condition affecting over 33 million patients globally. The company detailed its progress in building the necessary infrastructure for the trial and outlined a clear trajectory with imminent clinical milestones. FibroBiologics also emphasized its commitment to advancing its broader pipeline while ensuring a disciplined approach to resource allocation. The letter reflects a confident outlook on both current and future developments within the company.
Read more →FibroBiologics has announced the release of its CYWC628 drug product, which will be used in a Phase 1/2 clinical trial for diabetic foot ulcers. The product has been manufactured in compliance with FDA's cGMP and has passed all safety and quality tests. This milestone allows the company to begin enrolling patients for the trial, which aims to evaluate the drug's safety and efficacy.
Read more →FibroBiologics has reported promising preclinical results indicating that human dermal fibroblast (HDF) spheroids can effectively reprogram the burn wound environment. The treatment showed a significant reduction in inflammation and scar-forming activity within eight days post-injury. These findings suggest that HDF spheroids may enhance wound healing and minimize scarring, potentially advancing FibroBiologics' wound care platform.
Read more →FibroBiologics reported its financial results for Q1 2026 and provided a corporate update highlighting key progress in its clinical development. The company announced the completion of cGMP manufacturing for its CYWC628 product aimed at treating diabetic foot ulcers and reported positive preclinical results for its burn and degenerative disc disease programs. Additionally, FibroBiologics successfully raised $3 million and regained compliance with Nasdaq requirements. The focus moving forward includes the initiation of clinical trials and advancing its therapeutic pipeline.
Read more →FibroBiologics, Inc. announced that it will present preclinical data from its CYPS317 program for psoriasis at the Society for Investigative Dermatology Annual Meeting 2026. The presentation is scheduled for May 15, 2026, in Chicago, Illinois. This event showcases the company's commitment to developing innovative therapies for chronic diseases.
Read more →FibroBiologics, Inc. has confirmed compliance with Nasdaq listing requirements, resolving previous issues. The company meets the necessary criteria for continued listing, including stockholders' equity and bid price requirements. FibroBiologics will continue trading under the symbol 'FBLG' but will undergo monitoring for the next year.
Read more →FibroBiologics has unveiled its thymus organoid platform, showcasing preclinical data that highlights its potential to reverse age-related immune decline by restoring thymic function. Presented at the Keystone Symposia on Aging and Immunity, the platform enables the generation of various T cell lineages and demonstrates significant anti-tumor efficacy in mouse models. This innovation could address critical health issues related to immune decline and offer therapeutic avenues following chemotherapy or addressing congenital conditions linked to thymic loss.
Read more →FibroBiologics, Inc. has announced the successful closing of a public offering, raising approximately $3 million. The offering included 2,272,728 shares of common stock and warrants, with potential additional proceeds if the warrants are exercised. The company plans to use the funds for working capital and general corporate purposes, while also highlighting its extensive patent portfolio.
Read more →FibroBiologics, Inc. has announced the pricing of a public offering of 2,272,728 shares at $1.32 each, aiming to raise about $3 million. The offering includes warrants for the same number of shares, exercisable upon stockholder approval. The proceeds will be used for working capital and corporate purposes, with closing expected by April 2, 2026.
Read more →FibroBiologics announced the successful manufacturing of the CYWC628 drug product, which is set to support upcoming first-in-human clinical trials for diabetic foot ulcers. This marks a significant milestone as it represents the first large-scale CGMP manufacturing of a fibroblast-based spheroid therapeutic. The company plans to initiate Phase 1/2 clinical trials in the first half of 2026.
Read more →FibroBiologics, Inc. announced a 1-for-20 reverse stock split effective March 30, 2026, to comply with Nasdaq's bid price requirement. This decision, approved by stockholders, aims to enhance investor interest and will reduce the total number of outstanding shares significantly. The company will maintain its existing ticker symbol, FBLG.
Read more →FibroBiologics has announced advancements in its burn treatment program using proprietary fibroblast spheroid technology. The treatment, CYWC628, showed promising results in preclinical models, significantly increasing IL-10 levels and reducing IL-1B, indicating potential for enhanced healing. The company aims to address unmet needs in burn care and integrate this program into its broader wound care strategy.
Read more →FibroBiologics has completed site onboarding for its Phase 1/2 clinical trial of CYWC628, aimed at treating refractory diabetic foot ulcers. The trial will evaluate the safety and efficacy of this innovative fibroblast-based therapy. An interim analysis will assess primary endpoints after six weeks of treatment. The company is collaborating with Southern Star Research to ensure effective trial management.
Read more →FibroBiologics, Inc. announced the issuance of U.S. Patent No. 12,544,407 B2 for its fibroblast cell therapy aimed at treating osteoporosis. The patent covers various methods of administering fibroblast cells to modulate bone remodeling. This development reinforces the company's strategy in regenerative medicine and highlights the therapeutic potential of fibroblasts in addressing bone-related disorders.
Read more →FibroBiologics, a clinical-stage biotechnology company, will present at the BIO Investment & Growth Summit on March 2-3, 2026. CEO Pete O'Heeron is scheduled to speak at 10:15 a.m. ET on March 2. The company focuses on developing treatments for chronic diseases using fibroblast technology and holds a substantial number of patents.
Read more →FibroBiologics reported its full year 2025 financial results and outlined plans for a Phase 1/2 clinical trial in Australia targeting diabetic foot ulcers in 2026. The company improved its financial standing through direct offerings and is focused on advancing its fibroblast-based therapies. CEO Pete O'Heeron emphasized the importance of generating critical data for chronic disease treatments.
Read more →FibroBiologics, Inc. has been granted an extension by a Nasdaq Hearings Panel to regain compliance for its listing on The Nasdaq Capital Market. The company must meet specific financial criteria by set deadlines to maintain its listing. This extension provides a favorable opportunity for FibroBiologics to continue trading under the ticker FBLG.
Read more →FibroBiologics' Chairman and CEO, Pete O'Heeron, will present at the A4LI's H-SPAN Summit at Georgetown University from June 29 to July 1, 2026. The summit focuses on advancing legislative and scientific initiatives for healthier human lifespans. O'Heeron will discuss breakthroughs in longevity science and the importance of aligning scientific innovation with policy action.
Read more →FibroBiologics has announced the issuance of a Canadian patent for a novel fibroblast-based treatment for cachexia. This patent enhances the company's intellectual property portfolio and highlights its commitment to developing innovative therapies for chronic diseases. The treatment aims to address the significant unmet medical need associated with cachexia, which is projected to become a $3.2 billion market by 2032.
Read more →FibroBiologics, a clinical-stage biotechnology company, announced its participation in the DealFlow Discovery Conference scheduled for January 28-29, 2026. CEO Pete O'Heeron will present the company's advancements and engage in one-on-one investor meetings. The company focuses on developing therapies for chronic diseases using fibroblast technology.
Read more →FibroBiologics, a clinical-stage biotechnology company, announced that its CEO, Pete O'Heeron, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference on January 11, 2026. The event will take place at The St. Regis in San Francisco, California. FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblast-derived materials, boasting over 270 patents in various clinical pathways.
Read more →FibroBiologics announced positive preclinical results for its FSdC spheroid therapy aimed at treating degenerative disc disease. The therapy demonstrated significant improvements in intervertebral disc integrity in animal models. The company plans to advance this promising therapy toward clinical trials, highlighting its potential to transform spinal health management.
Read more →FibroBiologics has submitted an IND application to the FDA for CYPS317, a fibroblast spheroid-based therapy targeting moderate to severe psoriasis. This marks a significant step in their clinical development pipeline, following promising preclinical results that suggest the therapy may outperform existing treatments. The company aims to initiate first-in-human trials pending FDA review.
Read more →FibroBiologics, Inc. (Nasdaq: FBLG) has successfully closed a registered direct offering priced at $0.33 per share, generating approximately $1.7 million. This offering included an additional private placement of unregistered warrants that could provide another $1.7 million in gross proceeds if exercised. The company aims to use the net proceeds for working capital and general corporate purposes. The issuance of the warrants is dependent on Stockholder Approval, which adds a level of uncertainty to these potential proceeds.
Read more →FibroBiologics has announced a registered direct offering of 5,227,275 shares at $0.33 each, aiming to raise approximately $1.7 million. Concurrently, the company will issue unregistered warrants for the same number of shares at the same price. The offering is subject to stockholder approval and customary closing conditions, with proceeds intended for working capital.
Read more →FibroBiologics has filed a patent application for a fibroblast-derived therapy platform aimed at treating orthopedic and musculoskeletal conditions. The application, titled 'Spheroids For Cartilage Repair', seeks to protect innovative technology that promotes tissue repair. The company aims to address significant market needs in degenerative disc disease and joint restoration.
Read more →FibroBiologics has successfully paid off its outstanding convertible promissory notes, enhancing its financial stability. This milestone allows the company to focus on advancing its clinical programs, including a Phase 1/2 trial for its fibroblast-based product candidate. The company also plans to submit Investigational New Drug applications for treatments targeting psoriasis and multiple sclerosis.
Read more →FibroBiologics, Inc. has successfully closed a registered direct offering, raising approximately $1.5 million by selling 4,477,614 shares at $0.335 each. In conjunction, the company also issued unregistered warrants that could potentially generate an additional $1.5 million if exercised. The funds are intended for working capital and corporate purposes. However, the exercise of these warrants is contingent on stockholder approval and involves inherent uncertainties.
Read more →FibroBiologics, a clinical-stage biotechnology company, announced a $1.5 million registered direct offering priced at $0.335 per share under Nasdaq rules, set to be closed by November 25, 2025. This offering includes a concurrent private placement of unregistered warrants also priced at $0.335, which could raise an additional $1.5 million if exercised. The proceeds will be utilized for working capital and corporate purposes. However, the successful completion of the offering is contingent on obtaining Stockholder Approval, with no guarantees on the exercise of the warrants.
Read more →FibroBiologics has received HREC approval for a Phase 1/2 clinical trial of CYWC628, targeting refractory diabetic foot ulcers. The trial will enroll 120 patients across 10 sites in Australia, assessing the safety and efficacy of the investigational therapy. This milestone is seen as a significant step towards developing new cell therapies for chronic wounds.
Read more →FibroBiologics, Inc. has successfully closed a $4 million registered direct offering with an existing shareholder, selling shares and pre-funded warrants at $0.3303 each. The unique purchase involved payment using sovereign gold coins, which the company plans to liquidate for cash. Concurrently, they issued unregistered warrants for further shares, contingent on stockholder approval. Proceeds from the offering will be utilized for general corporate purposes and to address company debt.
Read more →FibroBiologics has announced a registered direct offering priced at-the-market, totaling approximately $4 million. This offering includes the sale of common stock and pre-funded warrants to an existing shareholder, allowing the company to strengthen its capital structure. The funding is intended for general corporate purposes and to address debt. A concurrent private placement will also issue unregistered warrants, subject to stockholder approval, for additional capital potential.
Read more →FibroBiologics reported its third quarter 2025 financial results, highlighting preparations for the Phase 1/2 clinical trial of CYWC628 for diabetic foot ulcers. The company is also preparing to submit Investigational New Drug applications for treatments targeting psoriasis and multiple sclerosis. CEO Pete O'Heeron emphasized the focus on advancing their fibroblast platform as a scalable technology.
Read more →FibroBiologics, a clinical-stage biotechnology company, will present at the Bio-Europe 2025 conference in Vienna, Austria. CEO Pete O’Heeron is scheduled to speak on November 4, 2025, at 4:15 p.m. CET. The company is focused on developing therapies for chronic diseases using fibroblast technology and has a significant patent portfolio.
Read more →FibroBiologics, a clinical-stage biotechnology company, will present at the 2025 ThinkEquity Conference on October 30. CEO Pete O'Heeron will deliver the presentation at 4:30 p.m. ET, with opportunities for one-on-one investor meetings. The company focuses on developing therapeutics for chronic diseases using fibroblast technology.
Read more →FibroBiologics, a clinical-stage biotechnology company, announced that its Chief Scientific Officer, Dr. Hamid Khoja, will present at the 2025 Cell & Gene Meeting on the Mesa in Phoenix, Arizona. The presentation will focus on the company's fibroblast-based technologies and their potential to address unmet medical needs. Additionally, FibroBiologics plans to initiate a clinical trial for diabetic foot ulcers in early 2026.
Read more →FibroBiologics has published an opinion editorial advocating for fibroblast cells as a superior alternative to traditional stem cell therapies for chronic diseases. Authored by company leadership, the article outlines the scientific advantages of fibroblasts, including faster proliferation and better immune modulation. The editorial suggests a significant shift in treatment paradigms, emphasizing the potential for improved patient outcomes.
Read more →FibroBiologics announced positive updates from its psoriasis research program, showcasing the effectiveness of human dermal fibroblast (HDF) spheroids in treating chronic-relapse psoriasis. A single administration of HDF spheroids matched the efficacy of multiple doses of an anti-IL-23 monoclonal antibody. The company is exploring further research to enhance treatment approaches and aims to develop long-term solutions for patients.
Read more →FibroBiologics has announced advancements in its Bone Marrow Organoid platform, which may provide new treatment options for hematopoietic cancers and age-related immune decline. The platform's versatility could enable the in-vivo generation of advanced cell therapies. The company is laying the groundwork for IND-enabling preclinical development, aiming for clinical advancement.
Read more →FibroBiologics, a clinical-stage biotechnology firm, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10. CEO Pete O'Heeron is scheduled to speak on September 10 at 12:00 p.m. ET and will also participate in one-on-one investor meetings during the event. The company specializes in developing therapies for chronic diseases using fibroblast technology.
Read more →FibroBiologics, a biotechnology company focused on chronic disease therapies, reported its financial results for Q2 2025 and provided a corporate update. The company secured an additional $5 million in financing to support its R&D efforts, including an upcoming Phase 1/2 trial for diabetic foot ulcers. Notably, the company presented promising pre-clinical evidence supporting fibroblast spheroids in reducing psoriasis severity at a major dermatology meeting. However, FibroBiologics also reported a net loss of $9.6 million for the first half of 2025, reflecting increased expenses in research and administration.
Read more →FibroBiologics has filed a patent application for methods to generate multipotent cells from donor-derived fibroblasts. This advancement aims to address challenges in regenerative treatments by allowing for scalable production of these cells. The patent could enhance the company's therapeutic development across various chronic diseases.
Read more →FibroBiologics, Inc. (Nasdaq: FBLG) will present its innovative fibroblast-based technology at the Advanced Wound Care Summit USA in Boston on July 15, 2025. CEO Pete O'Heeron will discuss recent advances in wound healing and psoriasis treatments, particularly focusing on their CYWC628 therapy for diabetic foot ulcers. The upcoming Phase 1/2 clinical trial aims to explore the therapy's potential to leverage the body's natural regenerative processes. The summit will convene leaders in the wound care field to advance chronic wound management solutions.
Read more →FibroBiologics, Inc. has confirmed its capacity to manufacture CybroCell™, a therapy aimed at treating degenerative disc disease (DDD), from its existing CYWC628 master cell bank. This significant advancement allows for a faster and cost-effective manufacturing process, supporting the amendment of its IND clearance with the FDA for a Phase I clinical trial. The company emphasizes the potential of its fibroblast-based platform to tackle various chronic conditions, highlighting progress in its clinical programs and the scalability of its solutions.
Read more →FibroBiologics, a clinical-stage biotechnology company, is set to host a live investor webinar on July 10, 2025. The event will feature CEO Pete O'Heeron discussing the company's fibroblast-based cell therapy platform aimed at treating chronic diseases. The presentation will highlight the promising pipeline, including candidates for diabetic foot ulcers and degenerative disc disease. Attendees will have the chance to engage in a live Q&A session following the discussion.
Read more →FibroBiologics, a clinical-stage biotechnology firm, has announced the closure of a $5 million tranche of their total $25 million financing through a Standby Equity Purchase Agreement with Yorkville Advisors. The funds are intended for general corporate use, including R&D and an impending clinical trial for diabetic foot ulcers anticipated to begin in the latter half of 2025. This financing marks a significant step in FibroBiologics' ongoing development in treating chronic diseases using fibroblast technology.
Read more →FibroBiologics, Inc. announced that its CEO, Pete O’Heeron, will present a company update at the BIO International Convention 2025. The presentation will cover milestones and advancements in fibroblast technology for treating chronic diseases such as multiple sclerosis and psoriasis. Notably, the company plans to initiate a Phase 1/2 clinical trial for diabetic foot ulcers later this year, emphasizing the potential of fibroblast therapies to address underlying health issues.
Read more →FibroBiologics has appointed Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance and capital markets, essential for guiding the company as it approaches its Phase 1/2 clinical trial for diabetic foot ulcers. His track record includes successful fundraising initiatives and optimizing public company governance. The company holds over 275 patents and aims to innovate therapeutics for chronic diseases.
Read more →FibroBiologics, a biotechnology company, presented its research at the Society for Investigative Dermatology Annual Meeting in San Diego. The focus was on the potential of human dermal fibroblast spheroids in treating psoriasis, highlighting preclinical data that suggests a durable cell-based therapy with unique immunomodulatory effects. The Chief Scientific Officer emphasized the need for effective long-term treatments for psoriasis, showcasing FibroBiologics' commitment to innovation in cell-based therapies. The presentation aims to advance understanding and approaches to chronic inflammatory diseases.
Read more →FibroBiologics, a clinical-stage biotechnology company, reported its first quarter 2025 financial results, highlighting significant progress in its research and development. The completion of a master cell bank and the opening of a new laboratory in Houston are notable developments that will support upcoming clinical trials. The company also demonstrated advancements in neurodegenerative disease treatments, with successful animal model studies. Additionally, FibroBiologics plans to initiate a Phase 1/2 clinical trial in Australia for diabetic foot ulcers later this year.
Read more →FibroBiologics announced the presentation of research at the ThymUS 2025 Meeting in Hawaii focusing on advancements in thymus organoid development. Simon Gebremeskel showcased a method for creating functional T cells through a transplantable thymus organoid. The research highlights the potential of fibroblasts to improve the success of organoid-based therapies. A cautionary note informs readers of inherent risks associated with forward-looking statements related to R&D efforts.
Read more →FibroBiologics, Inc. announced that Dr. Hamid Khoja will present their fibroblast cell-based therapeutic at The Cell & Gene Meeting on the Mediterranean in Rome. The presentation aims to discuss their approach to treating chronic diseases through immune system restoration. This event gathers leaders from the Advanced Therapy Medicinal Products community, illustrating the significance of FibroBiologics' work in the field. The conference will take place from April 15-17, 2025.
Read more →FibroBiologics has announced the opening of a new laboratory facility in Houston, designed to enhance its research and development capabilities for fibroblast-based therapeutics targeting chronic diseases. The expansion includes over 10,000 square feet of lab space, increasing the company's capacity to develop treatment candidates and potentially bringing manufacturing in-house. The initiative aims to accelerate innovation and improve efficiency in their research efforts, supported by plans to hire more researchers. CEO Pete O'Heeron highlighted that this move is a significant step towards achieving the company's mission of delivering life-changing therapies more effectively.
Read more →FibroBiologics has announced a significant scientific advancement demonstrating that intravenous fibroblasts can support remyelination in a Cuprizone animal model. Their findings indicated a statistically significant increase in myelin expression within seven weeks of treatment, confirming previous studies conducted on different models. This research enhances the understanding of fibroblasts' regenerative capabilities, offering potential new therapies for patients suffering from demyelinating diseases such as multiple sclerosis. The company's dedication to developing fibroblast-based treatments aims to address the root causes of chronic diseases.
Read more →FibroBiologics reported its financial results for the year 2024, highlighting a successful completion of its proprietary master cell bank for the fibroblast-based product candidate CYWC628. The company is preparing to initiate a Phase 1/2 clinical trial in Australia for diabetic foot ulcers, expected to start in Q2 2025. Financially, FibroBiologics recorded a reduced net loss of $11.2 million compared to the previous year, although both research and administrative expenses saw significant increases. Additionally, the company is expanding its patent portfolio and engaging in early-stage research related to human longevity.
Read more →FibroBiologics, a clinical-stage biotechnology firm, has announced its upcoming 2025 Annual Meeting of Stockholders scheduled for June 12, 2025, to be held virtually. The record date for stockholders eligible to vote is set for April 14, 2025. The company, based in Houston, specializes in developing treatments for chronic diseases using fibroblast cells, and currently holds over 160 patents across various therapeutic pathways.
Read more →FibroBiologics, a clinical-stage biotechnology company, will present its research on fibroblast-based therapies for chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting. Chief Scientific Officer Hamid Khoja will discuss the company's progress in utilizing fibroblasts for possible treatments, emphasizing their regenerative properties. The conference will take place in Freiburg, Germany, from March 26-28, 2025, providing a platform to showcase advancements in extracellular matrix biology.
Read more →FibroBiologics has filed a patent application for a novel method using fibroblast-based therapeutics to modulate mitochondrial activity. This innovative approach aims to address mitochondrial dysregulation, a condition linked to various chronic diseases. The company's focus on fibroblasts may unlock new treatment options and significantly impact how chronic diseases are treated. The potential benefits could enhance human longevity and improve the microenvironments of cells. However, there are associated risks regarding research outcomes and financial stability.
Read more →FibroBiologics and Charles River Laboratories announced the successful completion of a proprietary master cell bank, which will facilitate clinical trials for CYWC628, a cell therapy aimed at treating diabetic foot ulcers. This cell bank, manufactured under FDA regulations, is a crucial step in advancing fibroblast-based therapies. With this milestone, FibroBiologics is positioned to enhance its capabilities and collaborations in the rapidly evolving field of cell therapy. The upcoming phase I/II clinical trial is set to commence later this year, marking significant progress for the company.
Read more →FibroBiologics, a clinical-stage biotechnology company, will host an in-person analyst day on February 12, 2025, at the New York Marriott Marquis. The event will focus on the company’s research and development strategies, particularly its efforts to advance fibroblast-based therapeutics for chronic diseases. Presentations will be made by key management members, and a live Q&A session will follow. Additionally, the company will also participate in the 2025 BIO CEO & Investor Conference from February 10-11 in New York.
Read more →FibroBiologics, a clinical-stage biotechnology company headquartered in Houston, has closed the second $5 million tranche of its Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., part of a total financing plan of up to $25 million. This funding will support general corporate purposes and the development of therapeutics using fibroblasts. The company has 160+ patents related to chronic diseases and is positioned for future growth with these financial resources.
Read more →FibroBiologics, a clinical-stage biotech company, has entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors to raise up to $25 million over two years. The initial $15 million is available immediately, divided into three tranches. This financing will support various initiatives, including a first-in-human trial for diabetic foot ulcers and IND-enabling studies for psoriasis. CEO Pete O'Heeron indicated plans to leverage additional capital for further development in longevity and cancer treatments.
Read more →FibroBiologics, Inc. has entered into a Standby Equity Purchase Agreement with YA II PN LTD, allowing the company to sell up to $25 million of its common stock over two years. The initial funding of $5 million has been secured to support clinical trials for diabetic foot ulcers. Further tranches will be available contingent upon meeting specific conditions. The financing aims to enhance FibroBiologics' research and development capabilities in chronic disease treatments while also raising concerns about meeting the outlined conditions and the unpredictable nature of R&D outcomes.
Read more →FibroBiologics, a clinical-stage biotechnology company, has filed a patent application for a cell-based therapeutic aimed at treating splenomegaly. This condition, often associated with immune disorders, can lead to various health complications. The company emphasizes the potential of fibroblast therapies to support immune system regulation, which marks a significant milestone in their therapeutic development. The patent application suggests that FibroBiologics is positioning itself as a leader in addressing complex immune-related health issues.
Read more →FibroBiologics, a biotechnology company, has filed a patent application aimed at reducing blood clots associated with the inflammatory reaction known as IBMIR in cell-based therapies. This innovation seeks to enhance the safety and effectiveness of these treatments by targeting the body's inflammatory response. The patent outlines methods utilizing fibroblasts and other Tissue Factor-expressing cells to mitigate clotting and inflammatory complications. This advancement could transform existing therapeutic protocols and improve patient outcomes.
Read more →FibroBiologics reported its third quarter 2024 financial results, highlighting progress toward launching a Phase 1/2 clinical trial in Australia for its diabetes treatment candidate, CYWC628, expected to start in the second quarter of 2025. The company also announced the expansion of its patent portfolio, which now includes multiple new patents granted across various regions. Financially, FibroBiologics experienced an increase in net loss due to elevated research and administrative expenses. Despite the financial pressures, the company expressed optimism about the momentum in their clinical and R&D programs.
Read more →FibroBiologics, a clinical-stage biotechnology company, has announced notable updates on its artificial thymus organoid technology, which has shown strong potential in enhancing immune function. Recent results indicated that transplanted fibroblast-derived organoids can persist and function for over 50 days, generating a diverse range of mature T cells. The company highlighted the organoid's ability to support vascularization, critical for its sustained functionality. Leaders at FibroBiologics express optimism that this approach may lead to safer and more effective immunotherapies for patients with immune dysregulation.
Read more →FibroBiologics, Inc. has announced its participation in the upcoming 2024 ThinkEquity Conference and BIO-Europe 2024, where the company's senior leadership will present and engage in one-on-one meetings with investors. The company, based in Houston, is a clinical-stage biotech firm focused on developing treatments for chronic diseases, utilizing fibroblasts and fibroblast-derived materials. FibroBiologics holds over 160 patents, underscoring its commitment to medical advancement in cell therapy. The presentations will provide insight into the company’s significant pipeline and innovations in healthcare.
Read more →FibroBiologics has entered into a collaboration with Charles River Laboratories to manufacture its fibroblast cell-based therapies aimed at treating chronic diseases. The partnership stems from the successful completion of technology transfer and feasibility studies related to FibroBiologics’ therapeutic master cell bank. Through this agreement, Charles River will serve as the contract development and manufacturing organization, supporting the upcoming clinical trial for FibroBiologics’ product CYWC628 targeting diabetic foot ulcers, scheduled to begin in 2025. This collaboration represents a critical step for FibroBiologics in developing cutting-edge regenerative therapies.
Read more →FibroBiologics, Inc. announced the issuance of a patent from the European Patent Office for a novel method using modified fibroblasts to deliver anti-cancer agents. This method aims to improve the delivery of tumor-inhibiting agents directly to cancer cells, potentially enhancing treatment effectiveness. Executive comments underscore the therapeutic potential of fibroblasts in targeting challenging cancers. However, the company warns of various risks and uncertainties about the future performance and research outcomes related to this technology.
Read more →FibroBiologics, a clinical-stage biotechnology company, announced its participation in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. The event is scheduled for October 16, 2024, with CEO Pete O'Heeron representing the company. FibroBiologics has a strong focus on developing therapeutics for chronic diseases, backed by 160+ patents. This involvement in the summit highlights the company's commitment to advancing its position in the biotechnology field.
Read more →FibroBiologics, a clinical-stage biotechnology company, will present at the 2024 Cell & Gene Meeting on the Mesa in Phoenix, Arizona from October 7 to 9. Chief Scientific Officer Dr. Hamid Khoja will update on their pre-clinical studies focused on chronic wound healing and psoriasis. The presentation includes the development of their CYWC628 fibroblast spheroid candidate for diabetic foot ulcers, emphasizing the importance of fibroblasts in tissue repair. The company holds over 160 patents for various therapeutic applications including diabetes and cancer.
Read more →FibroBiologics, Inc. has engaged Southern Star Research as its clinical research organization in Australia to support the Phase 1/2 clinical trial of its product candidate, CYWC628, for treating diabetic foot ulcers. This partnership is viewed positively by both organizations, emphasizing Australia's strong clinical trial framework and the potential for CYWC628 to positively impact chronic wound healing. The CEO of FibroBiologics expressed optimism regarding the collaboration, while Southern Star Research aims to leverage its expertise to contribute to this innovative therapy's development. The engagement marks an essential development in FibroBiologics' growth and clinical strategies in the Asia Pacific region.
Read more →FibroBiologics has filed a patent application with the U.S. Patent Office for a technology that uses fibroblast cells to create three-dimensional hematopoietic organoids capable of generating various immune cells. This method is designed to be rapid, cost-effective, and scalable for therapeutic applications. The company aims to advance regenerative medicine and cancer treatments through this innovation. If granted, the patent could significantly enhance their capabilities in cell therapy development.
Read more →FibroBiologics, a clinical-stage biotechnology company based in Houston, will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. The presentation, conducted by Founder and CEO Pete O'Heeron, will be available on-demand for registered attendees. FibroBiologics specializes in developing treatments using fibroblast cells, with a robust patent portfolio supporting their work in various medical fields, including cancer and organ healing.
Read more →FibroBiologics, Inc. has filed a patent application for the use of fibroblast cell-based technology in adhesive bandages aimed at enhancing wound healing. The company's leaders believe that this innovation could revolutionize wound care, making advanced treatments more accessible. However, the announcement includes cautionary statements about risks related to the company's future performance, including challenges in funding and the unpredictability of research outcomes.
Read more →FibroBiologics, a clinical-stage biotechnology company, has submitted its Quarterly Report on Form 10-Q for the second quarter of 2024. The report is accessible on their website, highlighting the ongoing development of therapies using fibroblasts. FibroBiologics holds a significant number of patents for treatments targeting chronic diseases such as multiple sclerosis, psoriasis, and cancer. This filing demonstrates the company's commitment to transparency and regulatory compliance.
Read more →FibroBiologics, Inc. announced that its CEO Pete O'Heeron will present at the JonesTrading Healthcare Seaside Summit from July 14-16, 2024, in San Diego. The company is focused on developing therapeutics and potential cures for chronic diseases through fibroblast technology. It boasts a robust patent portfolio of over 150 issued and pending patents, reflecting its innovative position in the biotechnology field. This event provides an opportunity for FibroBiologics to showcase its advancements in regenerative medicine.
Read more →FibroBiologics has announced a preliminary proof of concept for a novel artificial thymus organoid technology designed to restore immune function in a mouse model of severe combined immunodeficiency (SCID). This organoid, constructed from fibroblasts and thymus-derived cells, has demonstrated the ability to generate mature T cells in both in vitro and in vivo conditions. The company aims to develop this technology for patients experiencing thymus function loss due to age or chemotherapy, which could significantly impact the treatment landscape for immune-related conditions. With over 150 patents, FibroBiologics is positioned as a leader in regenerative medicine and hopes to advance this technology further.
Read more →FibroBiologics, Inc. has announced its upcoming inclusion in the Russell 2000 Index, effective July 1, 2024. This decision reflects the company's growing market capitalization and is expected to enhance its visibility and liquidity in the investment community. CEO Pete O'Heeron emphasized that this recognition bolsters confidence in their technological advancements in fibroblast-based therapies. The annual reconstitution of the Russell Indexes allows for accurate reflections of market dynamics, serving as a benchmark for trillions in assets.
Read more →FibroBiologics, Inc. announced that Chief Scientific Officer Dr. Hamid Khoja will present research on wound care and psoriasis at the Extracellular Matrix Pharmacology Congress in Copenhagen, Denmark, taking place from June 17-19, 2024. The company focuses on utilizing fibroblasts for developing therapeutics to address chronic diseases. During the event, they will highlight their progress in fibroblast-derived therapies, which are anticipated to transform treatment approaches for conditions like psoriasis and chronic wounds. The presentation will include details on the use of fibroblast spheroids in therapeutic applications.
Read more →FibroBiologics, a clinical-stage biotechnology company, has announced its 2024 Annual Meeting of Stockholders, which will be held virtually on August 27, 2024. The record date for stockholders eligible to vote at the meeting is set for July 1, 2024. The company is recognized for its development of therapeutics and potential cures for chronic diseases, supported by over 150 patents issued and pending in various clinical pathways.
Read more →FibroBiologics, Inc. has filed its Quarterly Report on Form 10-Q for the first quarter of 2024, detailing its ongoing projects and financials. The report highlights the company's commitment to developing therapies for chronic diseases through fibroblast technology. FibroBiologics holds over 150 patents, illustrating its strong intellectual property portfolio and innovative approach to regenerative medicine. The filing reflects the company's dedication to transparency and regulatory compliance.
Read more →FibroBiologics, Inc. is set to present at the 2024 BIO International Convention, highlighting its recent business and clinical advancements. CEO Pete O’Heeron will showcase the company's progress as a public entity since its direct listing in January. The presentation is scheduled for June 4, 2024, at 11:45 a.m. PDT in San Diego, California. The company focuses on developing fibroblast-based therapies for chronic diseases, backed by over 150 patents.
Read more →The article outlines the current pipeline of FBLG, highlighting the late pre-clinical development of CYWC628 for wound healing. In studies conducted on diabetic mice, CYWC628 demonstrated significant improvement in wound healing compared to untreated controls and surpassed the efficacy of the FDA-approved product Grafix. The results from multiple phases of pre-clinical studies emphasize the therapeutic potential of CYWC628 in treating wounds. Additionally, ongoing developments in treatments for multiple sclerosis and degenerative disc disease were mentioned.
Read more →FibroBiologics, Inc. has announced a collaboration with Charles River Laboratories for the development and manufacturing of fibroblast-based therapies. This partnership, which includes a letter of intent for technology transfer and validation, is expected to advance the company's clinical trials focused on chronic diseases. Charles River will conduct feasibility studies and may become the contract development and manufacturing organization (CDMO) for FibroBiologics' drug products, subject to further agreements. The collaboration supports FibroBiologics' mission to develop innovative treatments using their patented fibroblast technology.
Read more →FibroBiologics, Inc. has received a patent from the Australian Patent Office for a method aimed at regenerating cartilage-type cells. This proprietary technique could address cartilage damage, an issue known for its limited healing capacity. The company emphasizes that this advancement enhances their position in the cell therapy market, particularly for disc repair and regeneration. However, they acknowledge inherent risks and uncertainties associated with their future research and business operations.
Read more →FibroBiologics, a biotechnology company, announced positive findings from a study on the therapeutic efficacy of dermal fibroblast spheroids in treating chronic wounds, specifically in a diabetes mouse model. The data will be presented at the Advanced Wound Care Summit USA in Boston on April 16-17, 2024. Key results demonstrate a 60% reduction in wound area after treatment within four days, suggesting a potential new approach for treating diabetic foot ulcers. The findings also highlight the modulation of cytokines and growth factors, which are crucial for healing. This research could significantly benefit the healthcare challenges associated with diabetic wounds.
Read more →FibroBiologics, a biotechnology company, has filed a patent application for its fibroblast-based technology, potentially targeting lupus treatment. The company's leadership expresses optimism about the role of fibroblasts in immune modulation and their ability to regulate pathogenic immune cells. However, the announcement includes caution about the uncertainties in research outcomes and the unpredictability of clinical study results, reflecting the inherent risks in biotechnology development.
Read more →FibroBiologics is set to present promising data at the 2024 ACTRIMS Forum in Florida, focusing on the potential of human dermal fibroblasts (HDFs) to treat multiple sclerosis (MS). The company has conducted extensive preclinical studies indicating that HDFs could effectively suppress pathogenic T cell activation and stimulate repair of the damaged myelin sheath. Initial phase 0/1 clinical trials reported no adverse events, bolstering the optimism about HDFs as a viable treatment option for MS. FibroBiologics aims to further investigate this potential through a planned phase II clinical trial with multiple-dose treatments.
Read more →FibroBiologics presented encouraging preclinical findings at the 2024 Keystone Symposia regarding their use of human dermal fibroblast (HDF) spheroids for treating psoriasis. The data demonstrated a significant reduction in the severity of skin lesions in a mouse model, indicating a 35% decrease in the Psoriasis Area and Severity Index score. The research suggests that HDF spheroids not only impact psoriasis severity but may also influence systemic autoimmune inflammation, showcasing a potential new avenue for cell therapy in chronic diseases.
Read more →FibroBiologics has announced the issuance of three new patents from the United States Patent Office, which will strengthen its portfolio in the field of fibroblast technology. The patents cover methods for cartilage repair, treatment of disc degenerative diseases, and gene therapy for the regeneration of cartilage cells. With over 150 patents now in their portfolio, the company aims to enhance protections for its innovative treatments targeting chronic diseases. CEO Pete O'Heeron emphasized the potential of these patents and their relevance to the U.S. market, the largest for their therapeutic candidates.
Read more →FibroBiologics has announced the issuance of three new patents from the Japan Patent Office, focusing on enhancing fibroblast therapeutic activity, augmenting regenerative activity, and the interactions between fibroblasts and immune cells. This addition strengthens the company's patent portfolio and asserts its leadership in the cell therapy space, particularly in Japan. CEO Pete O'Heeron emphasized the importance of these patents for future growth and innovation in treating chronic diseases.
Read more →FibroBiologics, a clinical-stage biotechnology company, announced the commencement of trading on NASDAQ under the ticker FBLG as of January 31, 2024. This event follows the effectiveness of its registration statement filed with the U.S. Securities and Exchange Commission on January 24, 2024. The company specializes in creating therapeutics for chronic diseases, leveraging fibroblasts and fibroblast-derived materials. FibroBiologics has a significant intellectual property portfolio with over 150 patents, marking its innovative potential in the regenerative medicine field.
Read more →